Observational study on dipeptidyl peptidase-4 inhibitors: A real-life analysis on 360 patients from the ASL VCO territory in Italy

Clinical Drug Investigation

Volumn 34, Issue 7, 2014, Pages 513-519

  Saglietti, Giuseppe ^a   Placentino, Giuseppe ^a   Schellino, Antonella ^a  

^a Pediatra di Libera Scelta   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; LIPID; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; ITALY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG TOLERANCE; ENZYMOLOGY; METABOLISM;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG TOLERANCE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84904066782     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0196-z     Document Type: Article

References (33)

1. International Diabetes Federation. Diabetes Atlas. 2013. http://www.idf.org/diabetesatlas/. Accessed 14 Mar 2014.
2. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed 14 Mar 2014.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
5. Sinclair AJ, Paolisso G, Castro M, et al. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011;37(Suppl 3):S27-38.
6. Annali AMD 2012 - Analisi prospettica degli indicatori di qualità dell'assistenza del diabete in Italia (2004-2011). http://www.infodiabetes.it/ files/ANNALI-AMD/2012. Accessed 27 Sep 2013.
7. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.
8. Tourrel C, Bailbe D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001;50:1562-70.
9. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. 2008;68:2131-62.
10. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410-8.
11. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38:89-101.
12. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890-5.
13. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-87.
14. Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13:567-76.
15. Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-85.
16. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab. 2009;23:487-98.
17. Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet. 2010;375:1410-2.
18. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28:1936-40.
19. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249-55.
20. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93:103-9.
21. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947-54.
22. Kothny W, Shao Q, Groop PH, et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14:1032-9.
23. Schweizer A, Dejager S. Experience with vildagliptin in patients <75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther. 2013;4:257-67.
24. Irons BK, Weis JM, Stapleton MR, et al. An update in incretin-based therapy: a focus on dipeptidyl peptidase-4 inhibitors. Curr Diabetes Rev. 2012;8:169-82.
25. Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13:775-83.
26. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:1049-58.
27. Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27:863-9.
28. Schweizer A, Dejager S, Foley JE, et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population <75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13:55-64.
29. Strain WD, Lukashevich V, Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382:409-16.
30. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29:14-25.
31. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35.
32. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
33. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf. 2011;6:304-9.